2059952-75-7 Usage
Description
(E)-N-(4-(3,5-dimethoxystyryl)phenyl)-3-(3,4,5-trimethoxyphenyl)acrylamide is a complex chemical compound belonging to the acrylamide class. It features a unique molecular structure with styryl and trimethoxyphenyl groups, which may contribute to its potential applications in various fields, particularly pharmaceutical research and drug development. Due to its complex nature, it is crucial to handle this compound with care and adhere to safety protocols in a laboratory environment.
Uses
Used in Pharmaceutical Research:
(E)-N-(4-(3,5-dimethoxystyryl)phenyl)-3-(3,4,5-trimethoxyphenyl)acrylamide is used as a research compound for exploring its potential pharmaceutical applications. Its unique structure and properties may offer new avenues for drug development, particularly in targeting specific biological pathways or receptors.
Used in Drug Development:
In the drug development industry, (E)-N-(4-(3,5-dimethoxystyryl)phenyl)-3-(3,4,5-trimethoxyphenyl)acrylamide is used as a lead compound to identify new therapeutic agents. Its specific molecular features may provide insights into the design of novel drugs with improved efficacy and selectivity.
Check Digit Verification of cas no
The CAS Registry Mumber 2059952-75-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 2,0,5,9,9,5 and 2 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 2059952-75:
(9*2)+(8*0)+(7*5)+(6*9)+(5*9)+(4*5)+(3*2)+(2*7)+(1*5)=197
197 % 10 = 7
So 2059952-75-7 is a valid CAS Registry Number.
2059952-75-7Relevant articles and documents
Discovery of oral-available resveratrol-caffeic acid based hybrids inhibiting acetylated and phosphorylated STAT3 protein
Li, Shanshan,Zhang, Wenda,Yang, Yanwei,Ma, Ting,Guo, Jianpeng,Wang, Shanshan,Yu, Wenying,Kong, Lingyi
, p. 1006 - 1018 (2016)
Constitutive activation of STAT3 has been found in a wide variety of cancers and demonstrated as a very attractive therapeutic target. Disrupting both acetylation and phosphorylation of STAT3 protein was hypothesized to greatly deactivate STAT3, therefore, treating cancers. To demonstrate the hypothesis, two series of novel resveratrol-caffeic acid hybrids were designed aiming to regulate both acetylation and phosphorylation of STAT3 protein, which is also the first report of the synthetic inhibitors simultaneously regulating two biological reactions of STAT3 to our knowledge. Most of these compounds were demonstrated with preferential antitumor activity with low IC50values against two cancer cell lines. Particularly, compound 7d was found as an excellent STAT3 inhibitor with over 50-fold better potency than resveratrol and caffeic acid. Meanwhile, the novel derivatives significantly inhibited the proliferation and induced the apoptosis of tumor cells. Molecular docking further disclosed the binding modes of STAT3 with the inhibitors. In addition, compound 7d orally and significantly suppressed breast cancer 4T1 xenograft tumor growth in vivo, indicating its great potential as an efficacious drug candidate for human cancer therapy.
